All-In-One Screener Dividend Income Portfolio Ben Graham Lost Formula Canadian Faster Growers CEO Buys CEO Buys after Price Drop > 20% Dividend Growth Portfolio Dividend Income Portfolio Fast Growers Hedge Fund Guru Top 10 Aggregated High Quality High Quality Low Capex w ROE ROC min High Quality & Low Capex High Yield Insider Buys Historical High Dividend Yields International Gurus' Top Holdings James Montier Short Screen Margin Decliners Mega Caps Peter Lynch & Warren Buffett Peter Lynch Growth w Lower Valuation Peter Lynch S&L Traded Below Book PFCF Screener Piotroski Score Screener Predictable Growth Companies Profitable predictable margin expanders Stocks Sold w less Cash Good Companies The Stalwarts
All-In-One Screener S&P 500 Map S&P 500 Bubble S&P 500 Aggregate Buffett-Munger Screener Industry Overview Undervalued Predictable Benjamin Graham Net-Net 52-week/3Y/5Y Lows 52-week/3Y/5Y Highs Magic Formula(Greenblatt) Dividend Stocks Peter Lynch Screen S&P500 Grid Predictable Companies Spin Off List Historical Low P/B List Historical Low P/S List High Short Interest Upcoming Special Dividends Delisted Stocks
Model PortfoliosPerformances Undervalued Predictable Buffett-Munger Low P/S Low P/B 52w Low Predictable Broadest Owned Most Weighted
Latest Guru Picks List of Gurus Real Time Picks Guru Portfolio Top 10 Holdings View Guru Bargains Hot Picks Aggregated Portfolio Consensus Picks ETFS Score Board Sector Picks International Picks Industry Trends Geographic Trend Options European Shorting
Buffett Indicator Industry Overview U.S. Treasury Yield Curve Shiller P/E Global Market Valuations Economic Data Shiller P/E by Sectors Buffett Assets Allocation GF Value for SP500 Index
The Dow Jones Industrial Average (DJIA) SP 500 Index Nasdaq Composite Index Gross Domestic Product (GDP) Shiller PE Ratio of Wilshire 5000 over GNP Civilian Unemployment Rate Russell 2000 Small Cap Price Index CBOE Volatility Index (VIX) Total Nonfarm Payrolls: All Employees More...
ORBIMED ADVISORS LLC Profile
Orbimed Advisors is an investment company that was founded in 1989 with a vision to “invest across the spectrum of healthcare companies from venture capital start-ups to large multinational companies.” The company started with its first public equity fund in 1989 and would expand to offer long/short equity and private equity investments by 1993. The company would continue to grow and expand, opening its Mumbai and Shanghai offices in Asia in 2007 and beginning its international expansion. In 2010, Orbimed Advisors would expand to the Middle East, opening an office in Israel. The company would then launch its first health care royalties and credit opportunities fund in 2011 and another royalty opportunities fund in 2015. Orbimed Advisors currently has approximately $15 billion in total assets under management spread across 5 accounts, all of which are discretionary. While its number of accounts has remained relatively steady in recent years, its total assets under management has increased significantly, growing from $1.2 billion back in 2010 to over 10 times that amount today. The company currently has 78 employees and has a partner board system of management with Samuel David Isaly, the original founder of the company, acting as the current managing partner for the firm. Samuel Isaly currently holds the controlling majority share in the company with his shares along making up over 50% of the ownership, with the rest of the ownership split amongst Sven Heinz Borho, Carl Lee Gordon, Jonathan Todd Silverstein, and various key executives, in order of decreasing ownership. Orbimed Advisors mostly provides its services to pooled investment vehicles, which makes up almost all of its client base, and also caters to investment companies. The company invests on a global scale, placing its assets almost exclusively in the health care sector, and invests in the materials, information technology, and finance sectors, among others, in order of decreasing allocation. The company’s strategies includes its Public Equity, Royalties Opportunities, and various private equity strategies focused in its key markets.
ORBIMED ADVISORS LLC has disclosed 172 total holdings in their latest 13F filing with the SEC for the portfolio date of 2021-09-30. The current portfolio value is calculated to be $9.09 Bil. The turnover rate is 12%.
In ORBIMED ADVISORS LLC's current portfolio as of 2021-09-30, the top 5 holdings are not including call and put options. ORBIMED ADVISORS LLC did not buy any new stocks in the current portfolio.
Please visit the "Current Portfolio" tab to see the current and past 13F holdings for ORBIMED ADVISORS LLC, as well as holding map, valuations for each stock, which positions are undervalued, have low PE Ratios, are considered high quality and recently traded at 52-week lows, etc.
Please visit the "Stock Picks" tab to see the latest guru trades and stock picks for ORBIMED ADVISORS LLC, which include data from 13F quarterly reports, 13D/G beneficial ownership reports and form 4 insider ownership change reports.
Please visit the "Summary" page to see the top 10 holdings, recent stock picks, performance, sector / industry breakdown details, as well as past holding history summary for ORBIMED ADVISORS LLC.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
GuruFocus Affiliate Program: Earn up to $400 per referral. Detailed
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.
© 2004-2022 GuruFocus.com, LLC. All Rights Reserved.